BIRC3 Expression Predicts CLL Progression and Defines Treatment Sensitivity via Enhanced NF-κB Nuclear Translocation.

Asslaber, D; Wacht, N; Leisch, M; Qi, Y; Maeding, N; Hufnagl, C; Jansko, B; Zaborsky, N; Villunger, A; Hartmann, TN; Greil, R; Egle, A;

http://www.ncbi.nlm.nih.gov/pubmed/30487125